CNTX

$0.19+2.93%

Context Therapeutics Inc.

Market Cap

$18M

Live price × SEC shares (Aug 3, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

1.77

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.5

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	8,722	11,841	7,015	12,530	40,108
Operating income	(10,610)	(13,805)	(9,344)	(14,967)	(48,726)
Net income	(9,693)	(13,026)	(8,681)	(14,558)	(45,958)
EPS (basic) ($)	(0.10)		(0.09)	(0.15)	(0.48)
EPS (diluted) ($)	(0.10)		(0.09)	(0.15)	(0.48)
Weighted avg. shares (basic)	95,185		95,184	95,184
Weighted avg. shares (diluted)	95,185		95,184	95,184

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 5, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 20 more quarters, back to Sep 2020, with Tormere Pro.